nach oben

Erschienen in:

01.12.2007 | Epidemiology

Quantitative exploration of possible reasons for the recent improvement in breast cancer survival

verfasst von: Sylvie Bérubé, Louise Provencher, Jean Robert, Simon Jacob, Nicole Hébert-Croteau, Julie Lemieux, Thierry Duchesne, Jacques Brisson

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Objective

Breast cancer mortality has been declining in many countries including Canada because of improvements in survival. This study attempts to explain observed trends in breast cancer survival with special attention given to the role of improvements in early detection and treatment.

Methods

This study is based on 4,312 women diagnosed with primary invasive breast carcinoma treated in a Canadian breast center between 1976 and 2000 and followed to the end of 2001. Observed and relative survival rates were calculated. Multivariate relative survival regression models were used to assess trends in breast cancer survival over the study period.

Results

The proportion of women with small tumors (≤10 mm) was higher in late 1990s, while that of women with regional involvement was lower compared to earlier periods. Adjuvant chemotherapy or endocrine therapy use increased steadily from 6.6% to 84.0% during the study period. Five-year relative survival rates ranged between 82.1% and 83.7% between 1976 and 1990, and increased thereafter to reach 87.6% in 1991–95, and 92.1% in 1996–2000. During the first five years after diagnosis, women diagnosed in 1991–95 and 1996–2000 experienced a reduction in breast cancer mortality of 28% (Relative Risk (RR)= 0.72; 95% CI: 0.59–0.89) and 49% (RR = 0.51; 95% CI: 0.39–0.68) respectively compared to women diagnosed in 1976–90. Improvement in breast cancer survival in 1990’s could not be explained by characteristics of women, biology of the tumor, advancements in early detection and type of initial treatments.

Conclusion

A substantial increase in breast cancer survival was observed in the 1990s but the reasons for this improvement remain elusive. Better knowledge of these reasons could help not only to further reduce the burden related to breast cancer but also the burden related to other major cancer sites.

Institut national de cancer du Canada. Statistiques canadiennes sur le cancer 2004. Toronto, Canada, avril 2004

Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6:229–239PubMedCrossRef

Ries LAG, Eisner MP, Kosary CL et al. SEER Cancer Statistics Review, 1975–2002, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2002/, based on November 2004 SEER data submission, posted to the SEER web site 2005

Surveillance, Epidemiology, End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality – All COD, Public-Use With State, Total U.S. (1969–2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005. Underlying mortality data provided by NCHS (www.cdc.gov/nchs)

Levi F, Lucchini F, Negri E et al (2004) Trends in mortality from major cancers in the European Union, including acceding countries, in 2004. Cancer 101:2843–2850PubMedCrossRef

Surveillance, Epidemiology, End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence – SEER 9 Regs Public-Use, Nov 2004 Sub (1973–2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission

Louchini R, Beaupré M La survie reliée au cancer pour les nouveaux cas déclarés au Québec, de 1984 à 1998: Survie observée et survie relative, 2003

Demers A, Turner D, Mo D et al (2005) Breast cancer trends in Manitoba: 40 years of follow-up. Chronic Dis Can 26:13–19PubMed

Ugnat AM, Xie L, Semenciw R et al (2005) Survival patterns for the top four cancers in Canada: the effects of age, region and period. Eur J Cancer Prev 14:91–100PubMedCrossRef

10.

Statistique Canada Statistiques sur la survie 2005. http://www.statcan.ca/francais/freepub/84–601-XIF/2005001/survival_f.htm. Access date: August 2005

11.

Ellison LF, Gibbons L (2004) Leading cancers–changes in five-year relative survival. Health Rep 15:19–32PubMed

12.

Coleman MP, Gatta G, Verdecchia A et al (2003) EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 14 Suppl (5):v128–v149PubMedCrossRef

13.

Kobayashi S (2004) What caused the decline in breast cancer mortality in the United Kingdom? Breast Cancer 11:156–159PubMedCrossRef

14.

Jatoi I, Miller AB (2003) Why is breast-cancer mortality declining? Lancet Oncol 4:251–254PubMedCrossRef

15.

Quinn MJ (2003) Cancer trends in the United States–a view from Europe. J Natl Cancer Inst 95:1258–1261PubMed

16.

Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359–377PubMed

17.

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef

18.

Lawless JF (1982) Statistical models and methods for lifetime data. Wiley series in probability and mathematical statistics. New York: John Wiley and Sons

19.

Ederer F, Axtell LM, Cutler SJ (1961) The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 6:101–121PubMed

20.

Surv3: Relative survival analysis program. Software Malual Program version 3.01. Helsinki: Finnish Cancer Registry

21.

Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62PubMedCrossRef

22.

Berrino F, Esteve J, Coleman MP (1995) Basic issues in estimating and comparing the survival of cancer patients. IARC Sci Publ:1–14

23.

Gamel JW, Vogel RL (2001) Non-parametric comparison of relative versus cause-specific survival in Surveillance, Epidemiology and End Results (SEER) programme breast cancer patients. Stat Methods Med Res 10:339–352PubMedCrossRef

24.

Capocaccia R, Gatta G, Roazzi P et al (2003) The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. Ann Oncol 14 Suppl (5):v14–v27PubMedCrossRef

25.

MacMahon S, Collins R (2001) Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 357:455–462PubMedCrossRef

26.

Louwman WJ, Janssen-Heijnen ML, Houterman S et al (2005) Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 41:779–785PubMedCrossRef

27.

Read WL, Tierney RM, Page NC et al (2004) Differential prognostic impact of comorbidity. J Clin Oncol 22: 3099–3103PubMedCrossRef

28.

Houterman S, Janssen-Heijnen ML, Verheij CD et al (2004) Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients. Br J Cancer 90:2332–2337PubMed

29.

Nagel G, Wedding U, Rohrig B et al (2004) The impact of comorbidity on the survival of postmenopausal women with breast cancer. J Cancer Res Clin Oncol 130:664–670PubMedCrossRef

30.

Yancik R, Wesley MN, Ries LA et al (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. Jama 285:885–892PubMedCrossRef

31.

Piccirillo JF, Tierney RM, Costas I et al (2004) Prognostic importance of comorbidity in a hospital-based cancer registry. Jama 291:2441–2447PubMedCrossRef

32.

Geraci JM, Escalante CP, Freeman JL et al (2005) Comorbid disease and cancer: the need for more relevant conceptual models in health services research. J Clin Oncol 23:7399–7404PubMedCrossRef

33.

Shen Y, Yang Y, Inoue LY et al (2005) Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 97:1195–1203PubMed

34.

Kerlikowske K (1997) Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit. J Natl Cancer Inst Monogr:79–86

35.

Fletcher SW, Elmore JG (2003) Clinical practice. Mammographic screening for breast cancer. N Engl J Med 348:1672–1680PubMedCrossRef

36.

Elmore JG, Armstrong K, Lehman CD et al (2005) Screening for breast cancer. Jama 293:1245–1256PubMedCrossRef

37.

Zackrisson S, Andersson I, Janzon L et al (2006) Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study. BMJ 332:689–692PubMedCrossRef

38.

Sant M, Allemani C, Capocaccia R et al (2003) Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer 106:416–422PubMedCrossRef

39.

Hebert-Croteau N, Brisson J, Lemaire J et al (2005) The benefit of participating to clinical research. Breast Cancer Res Treat 91:279–281PubMedCrossRef

40.

Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97:188–194PubMedCrossRef

41.

Tai P, Yu E, Vinh-Hung V et al (2004) Survival of patients with metastatic breast cancer: twenty-year data from two SEER registries. BMC Cancer 4:60PubMedCrossRef

42.

Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? Cancer 100:44–52PubMedCrossRef

43.

Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792PubMedCrossRef

44.

Reynolds T (1999) Declining breast cancer mortality: what’s behind it? J Natl Cancer Inst 91:750–753PubMedCrossRef

45.

Olivotto IA, Bajdik CD, Plenderleith IH et al (1994) Adjuvant systemic therapy and survival after breast cancer. N Engl J Med 330:805–810PubMedCrossRef

46.

Elkin EB, Hudis C, Begg CB et al (2005) The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975–1999. Cancer 104:1149–1157 PubMedCrossRef

47.

Huiart L, Bardou VJ, Puig B et al (2006) [Improvement in breast cancer survival between 1975 and 2003 in a cohort of 5722 women]. Bull Cancer 93:391–399PubMed

Titel: Quantitative exploration of possible reasons for the recent improvement in breast cancer survival
verfasst von: Sylvie Bérubé
Louise Provencher
Jean Robert
Simon Jacob
Nicole Hébert-Croteau
Julie Lemieux
Thierry Duchesne
Jacques Brisson
Publikationsdatum: 01.12.2007
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2007
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9503-1

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Quantitative exploration of possible reasons for the recent improvement in breast cancer survival